Oral pharmaceutical composition containing combination of PPARa and a HMG-CoA reductase inhibitor
AssigneeGalephar Pharmaceutical Research, Inc.
InventorsArthur Deboeck, Francis Vanderbist, Philippe Baudier, Antonio Sereno
Life of this patent
Estimating the term…
Abstract
Oral pharmaceutical composition containing, in the same pharmaceutical form, effective amounts of a HMG-CoA reductase inhibitor derivative and of PPARα, especially fenofibrate. Also described is the use of some inactive ingredients which allow to improve the dissolution and/or bioavailability of the drugs from the said composition.
Claims59
1-33. (canceled)
A pharmaceutical composition comprising in a same dosage form an amount of at least one peroxisome proliferator activated compound (PPARα), an amount of at least one HMG-CoA reductase inhibitor compound which is a statin family, and at least one polyglycolized glyceride.
A method of treating hyperlipidemia or hypercholesterolemia or both in human in need thereof, which comprises administering orally substantially simultaneously, an effective amount of at least one peroxisome proliferator activated compound (PPARα), an effective amount of at least one HMG-CoA reductase inhibitor compound of the statin family, and at least one glyceride compound.
Dependencies are inferred from the claim text.